Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.58 |
| ▸ | HTR2B | P41595 | 11/20 | 0.58 |
| ▸ | HTR2A | P28223 | 13/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5237943 | 0.99 | HTR2C (0.57) | HTR2CHTR2BHTR2ACYP1A2CYP2D6 | |
| SCHEMBL3865092 | 0.95 | KDM4E (0.58) | HTR2CHTR2BHTR2ACYP1A2CYP2D6 | |
| SCHEMBL1929865 | 0.86 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL4023281 | 0.85 | HTR2C (0.60) | HTR2CHTR2BHTR2A | |
| SCHEMBL5474831 | 0.85 | HTR2C (0.60) | HTR2CHTR2BHTR2A | |
| SCHEMBL3866392 | 0.84 | CYP1A2 (0.64) | HTR2CHTR2BHTR2ACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4024775 | 0.84 | HTR2C (0.59) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL5467936 | 0.84 | HTR2C (0.59) | HTR2CHTR2BHTR2A | |
| SCHEMBL3857018 | 0.83 | ADRA1A (0.51) | HTR2CHTR2BCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL212928 | 0.83 | HTR2C (0.59) | HTR2CHTR2BHTR2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1611098-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1611098-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| EP-1603914-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004089897-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004081010-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR4, HTR7, HTR2C | HTR2C 3/4885HTR2B 18/4885HTR2A 20/4885 |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HTR2C 2/4885HTR2B 25/4885HTR2A 17/4885 |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR2C, HTR4, HTR3C | HTR2C 1/4885HTR2B 18/4885HTR2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.